Marktanalyse - Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2017

Global Markets Direct
02.2017
176 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2017


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD) — Pipeline Review, H1 2017, provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline landscape.

Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease. Nonalcoholic fatty liver disease is common and, for most people, causes no signs and symptoms and no complications. But in some people with nonalcoholic fatty liver disease, the fat that accumulates can cause inflammation and scarring in the liver. The most common symptoms that bring NAFLD to medical attention are malaise, fatigue, and right upper quadrant or diffuse abdominal discomfort.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD) — Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 15, 8, 2, 16 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 7

Global Markets Direct Report Coverage 7

Non Alcoholic Fatty Liver Disease (NAFLD) - Overview 8

Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 14

Products under Development by Companies 15

Products under Development by Universities/Institutes 18

Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics Assessment 19

Assessment by Target 19

Assessment by Mechanism of Action 22

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Non Alcoholic Fatty Liver Disease (NAFLD) - Companies Involved in Therapeutics Development 29

Allergan Plc 29

Arisaph Pharmaceuticals Inc 29

AstraZeneca Plc 30

Betagenon AB 30

Bird Rock Bio Inc 31

Can-Fite BioPharma Ltd 31

Cerenis Therapeutics Holding SA 32

Conatus Pharmaceuticals Inc 32

Corcept Therapeutics Inc 33

CymaBay Therapeutics Inc 33

Daewoong Pharmaceutical Co Ltd 34

Dimerix Bioscience Pty Ltd 34

Dr. Falk Pharma GmbH 35

DURECT Corp 35

Enanta Pharmaceuticals Inc 36

Eternygen GmbH 36

Galmed Pharmaceuticals Ltd 37

Gemphire Therapeutics Inc 37

Genfit SA 38

Gilead Sciences Inc 38

Huons Co Ltd 39

Immuron Ltd 39

Kyorin Pharmaceutical Co Ltd 40

Matinas BioPharma Holdings Inc 40

Miyarisan Pharmaceutical Company Ltd 41

NovaTarg Therapeutics Inc 41

Pfizer Inc 42

Renova Therapeutics Inc 42

Sancilio & Company Inc 43

TaiwanJ Pharmaceuticals Co Ltd 43

TCM Biotech International Corp 44

Zydus Cadila Healthcare Ltd 44

Non Alcoholic Fatty Liver Disease (NAFLD) - Drug Profiles 45

(leucine + metformin hydrochloride + sildenafil citrate) - Drug Profile 45

(leucine + PDE5 Inhibitor) - Drug Profile 47

AC-261066 - Drug Profile 48

Aramchol - Drug Profile 49

ARI-3037MO - Drug Profile 55

AZD-4076 - Drug Profile 57

C-10 - Drug Profile 59

CBM-588 - Drug Profile 61

cenicriviroc mesylate - Drug Profile 63

CER-209 - Drug Profile 71

CORT-118335 - Drug Profile 72

dapagliflozin propanediol - Drug Profile 73

DMX-300 - Drug Profile 80

Drug to Antagonize MCJ for Gastrointestinal Disorders - Drug Profile 81

DUR-928 - Drug Profile 82

DWP-10292 - Drug Profile 86

EDP-305 - Drug Profile 87

elafibranor - Drug Profile 88

emricasan - Drug Profile 96

FLB-12 - Drug Profile 104

gemcabene calcium - Drug Profile 105

GS-0976 - Drug Profile 109

GS-9674 - Drug Profile 111

HTD-1801 - Drug Profile 114

HU-002 - Drug Profile 115

IMM-124E - Drug Profile 116

liothyronine sodium - Drug Profile 119

MAT-8800 - Drug Profile 120

MN-002 - Drug Profile 121

naltrexone hydrochloride - Drug Profile 123

Namacizumab - Drug Profile 125

namodenoson - Drug Profile 126

NLM-0100 - Drug Profile 131

norursodeoxycholic acid - Drug Profile 132

O-304 - Drug Profile 134

oltipraz - Drug Profile 136

PF-06835919 - Drug Profile 137

RT-200 - Drug Profile 138

RT-210 - Drug Profile 139

saroglitazar - Drug Profile 140

SC-410 - Drug Profile 142

seladelpar - Drug Profile 143

selonsertib - Drug Profile 147

Small Molecule for Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease - Drug Profile 149

Small Molecules for Non-Alcoholic Steatohepatitis and Non Alcoholic Fatty Liver Disease - Drug Profile 150

Small Molecules to Activate AMPK for Fatty Liver Disease - Drug Profile 151

Small Molecules to Inhibit NaCT for Metabolic Diseases - Drug Profile 152

Synthetic Peptides for Non Alcoholic Fatty Liver Disease and Non Alcoholic Steatohepatitis - Drug Profile 153

TCM-606F - Drug Profile 154

tipelukast - Drug Profile 155

Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects 160

Non Alcoholic Fatty Liver Disease (NAFLD) - Discontinued Products 161

Non Alcoholic Fatty Liver Disease (NAFLD) - Product Development Milestones 162

Featured News & Press Releases 162

Appendix 172

Methodology 172

Coverage 172

Secondary Research 172

Primary Research 172

Expert Panel Validation 172

Contact Us 172

Disclaimer 173





List of Tables

Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Allergan Plc, H1 2017

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Arisaph Pharmaceuticals Inc, H1 2017

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by AstraZeneca Plc, H1 2017

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Betagenon AB, H1 2017

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Bird Rock Bio Inc, H1 2017

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Can-Fite BioPharma Ltd, H1 2017

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Cerenis Therapeutics Holding SA, H1 2017

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Conatus Pharmaceuticals Inc, H1 2017

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Corcept Therapeutics Inc, H1 2017

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by CymaBay Therapeutics Inc, H1 2017

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Dimerix Bioscience Pty Ltd, H1 2017

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Dr. Falk Pharma GmbH, H1 2017

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by DURECT Corp, H1 2017

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Enanta Pharmaceuticals Inc, H1 2017

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Eternygen GmbH, H1 2017

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Galmed Pharmaceuticals Ltd, H1 2017

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Gemphire Therapeutics Inc, H1 2017

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Genfit SA, H1 2017

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Gilead Sciences Inc, H1 2017

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Huons Co Ltd, H1 2017

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Immuron Ltd, H1 2017

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Matinas BioPharma Holdings Inc, H1 2017

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Miyarisan Pharmaceutical Company Ltd, H1 2017

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by NovaTarg Therapeutics Inc, H1 2017

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Pfizer Inc, H1 2017

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Renova Therapeutics Inc, H1 2017

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Sancilio & Company Inc, H1 2017

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H1 2017

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by TCM Biotech International Corp, H1 2017

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017

Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects, H1 2017

Non Alcoholic Fatty Liver Disease (NAFLD) - Discontinued Products, H1 2017





List of Figures

Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus